Exane Derivatives’s BioNTech BNTX Stock Holding History

Exane Derivatives’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$119K	Buy	799 +95	+13%	+$14.5K	0.07%	248
2022 Q1	$120K	Buy	704 +108	+18%	+$18.1K	0.03%	443
2021 Q4	$154K	Buy	596 +63	+12%	+$17.3K	0.04%	390
2021 Q3	$145K	Buy	533 +185	+53%	+$58.8K	0.03%	467
2021 Q2	$72.3K	Sell	348 -630	-64%	-$119K	0.02%	583
2021 Q1	$107K	Hold	978	–	–	0.03%	415
2020 Q4	$79.7K	Buy	+978	New	+$96K	0.02%	423

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Exane Derivatives's BNTX Position: Q2 2022 in Review

Exane Derivatives increased its BioNTech (BNTX) stake by 13% in Q2 2022, buying an estimated $14.5K and bringing the position to 799 shares worth $119K. The position accounts for 0.07% of the portfolio, ranked #248.

Exane Derivatives first reported a position in BNTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $154K in Q4 2021. 292 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

Exane Derivatives held 799 shares of BioNTech worth $119K as of Q2 2022.
Exane Derivatives bought 95 BioNTech shares in Q2 2022, an estimated $14.5K.
BioNTech made up 0.07% of Exane Derivatives's portfolio in Q2 2022, its #248 holding.
Exane Derivatives first reported a position in BioNTech in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's BioNTech position peaked at $154K in Q4 2021.
292 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.